Oxford University scientists find a key to a new treatment for...

According to the official Oxford University website, a collaborative study led by Dr. Nora Bengoa Virginie of the Oxford Center for Parkinson’s Diseases showed that compounds known as molecular tweezers could become a promising treatment for modifying Parkinson’s disease.

The treatment previously showed a high potential to target toxic protein clumps that form in neurodegenerative conditions such as Alzheimer’s disease, so research teams investigated whether specific molecular forceps were present. CLR01, Was able to reduce protein clump formation in cell and mouse models of Parkinson’s disease.

Advertisements

The study showed that CLR01 Able to reduce Parkinson’s alpha-synuclein protein clusters and prevent the death of human neurons that were created from stem cells.

And the researchers tested CLR01 In a mouse model with Parkinson’s disease, it stimulates the formation of protein groups and mimics the motor symptoms experienced by people with the condition, which can include tremors and slow movement. As the mice age, reduce the treatment CLR01 Most importantly, from the emergence of motor problems and the formation of toxic protein groups in the brain, the team showed that a remedy CLR01 It was less effective in older animals with more advanced Parkinson’s disease.

This work demonstrates that early use of preventive treatments in Parkinson’s disease is essential for effective treatment. These pooled results highlight that: CLR01 It is a candidate for Parkinson’s disease, and highlights the need for more research in this area.

“The future investment in identifying the appropriate treatment window for these types of therapeutic agents is critical to the success of these and other therapeutic strategies,” said lead researcher, Dr. Nora Bengoa-Virginia.

Professor Richard Wade Martins, president of the Oxford Parkinson Center for Disease and lead author of the study, said: “This is very exciting work that shows that drug treatments can be developed to de-select toxic protein groups to preserve neurons in Parkinson’s models. Our work focuses on developing new approaches to saving neurons when they begin to lose their function. “Early on, but before you die later in this state, this is very exciting work showing that drug therapies can be developed to cancel the selection of toxic protein groups to preserve neurons in models of Parkinson’s disease.”